Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 15/20 | 0.60 |
| ▸ | FABP3 | P05413 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7122377 | 0.90 | FABP4 (0.51) | FABP4FABP3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL7134032 | 0.83 | FABP4 (0.49) | FABP4ALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL7131026 | 0.83 | SMN1; SMN2 (0.46) | FABP4HTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL8323387 | 0.81 | FABP4 (0.43) | FABP4FABP3HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL7130963 | 0.81 | PDE4D (0.48) | FABP4 | |
| SCHEMBL7163821 | 0.81 | SMN1; SMN2 (0.43) | FABP4HTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL7129686 | 0.80 | FABP4 (0.45) | FABP4FABP3 | |
| SCHEMBL5016426 | 0.77 | FABP4 (0.47) | FABP4ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL5016438 | 0.75 | CCR2 (0.47) | FABP4ALDH1A1 | |
| SCHEMBL6695776 | 0.75 | FABP4 (1.00) | FABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004069831-A1 | TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-08-19 | — | — | WO | disclosed |